Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observation...

Autores
Tang, Mengxuan; Ryman, Davis C.; McDade, Eric; Jasielec, Mateusz S.; Buckles, Virginia D.; Cairns, Nigel J.; Fagan, Anne M.; Goate, Alison; Marcus, Daniel S.; Xiong, Chengjie; Allegri, Ricardo Francisco; Chhatwal, Jasmeer P.; Danek, Adrian; Farlow, Martin R.; Fox, Nick C.; Ghetti, Bernardino; Graff-Radford, Neill R.; Laske, Christopher; Martins, Ralph N.; Masters, Colin L.; Mayeux, Richard P.; Ringman, John M.; Rossor, Martin N.; Salloway, Stephen P.; Schofield, Peter R.; Morris, John C.; Bateman, Randall J.
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background Autosomal dominant familial Alzheimer's disease (ADAD) is a rare disorder with non-amnestic neurological symptoms in some clinical presentations. We aimed to compile and compare data from symptomatic participants in the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) with those reported in the literature to estimate the prevalences of non-amnestic neurological symptoms in participants with ADAD. Methods We prospectively collected data from the DIAN-OBS database, which recruited participants from study centres in the USA, Europe, and Australia, between Feb 29, 2008, and July 1, 2014. We also did a systematic review of publications to extract individual-level clinical data for symptomatic participants with ADAD. We used data for age of onset (from first report of cognitive decline), disease course from onset to death, and the presence of 13 neurological findings that have been reported in association with ADAD. Using multivariable linear regression, we investigated the prevalences of various non-amnestic neurological symptoms and the contributions of age of onset and specific mutation type on symptoms. Findings The DIAN-OBS dataset included 107 individuals with detailed clinical data (forming the DIAN-OBS cohort). Our systematic review yielded 188 publications reporting on 1228 symptomatic individuals, with detailed neurological examination descriptions available for 753 individuals (forming the published data cohort). The most prevalent non-amnestic cognitive manifestations in participants in the DIAN-OBS cohort were those typical of mild to moderate Alzheimer's disease, including visual agnosia (55·1%, 95% CI 45·7–64·6), aphasia (57·9%, 48·6–67·3), and behavioural changes (61·7%, 51·5–70·0). Non-amnestic cognitive manifestations were less prevalent in the published data cohort (eg, visual agnosia [5·6%, 3·9–7·2], aphasia [23·0%, 20·0–26·0], and behavioural changes [31·7%, 28·4–35·1]). Prevalence of non-cognitive neurological manifestations in the DIAN-OBS cohort was low, including myoclonus and spasticity (9·3%, 95% CI 3·8–15·0), and seizures (2·8%, 0·5–5·9) and moderate for parkinsonism (11·2%, 5·3–17·1). By constrast, prevalence was higher in the published data cohort for myoclonus and spasticity (19·4%, 16·6–22·2 and 15·0%, 12·5–17·6, respectively), parkinsonism (12·5%, 10·1–15·0), and seizures (20·3%, 17·4–23·2). In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of onset of symptoms of ADAD (odds ratio 1·09 per 1 year increase in age of onset, 95% CI 1·04–1·14, p=0·0003); and motor symptoms were more common at younger age of onset (myoclonus 0·93, 0·90–0·97, p=0·0007; seizures 0·95, 0·92–0·98, p=0·0018; corticobulbar deficits 0·91, 0·86–0·96, p=0·0012; and cerebellar ataxia 0·82, 0·74–0·91, p=0·0002). In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stages of disease. Interpretation The non-cognitive clinical manifestations of Alzheimer's disease seem to affect a small proportion of participants with mild to moderate ADAD, and are probably influenced by disease severity, environmental, and genetic factors. When evaluating patients with potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disease are the most consistent finding, with some patients manifesting non-cognitive neurological symptoms. Future work is needed to determine the environmental and genetic factors that cause these neurological symptoms. Funding National Institutes of Health and German Center for Neurodegenerative Diseases.
Fil: Tang, Mengxuan. Washington University. School of Medicine; Estados Unidos
Fil: Ryman, Davis C.. Washington University. School of Medicine; Estados Unidos
Fil: McDade, Eric. Washington University. School of Medicine; Estados Unidos
Fil: Jasielec, Mateusz S.. Washington University. School of Medicine; Estados Unidos
Fil: Buckles, Virginia D.. Washington University. School of Medicine; Estados Unidos
Fil: Cairns, Nigel J.. Washington University. School of Medicine; Estados Unidos
Fil: Fagan, Anne M.. Washington University. School of Medicine; Estados Unidos
Fil: Goate, Alison. Washington University. School of Medicine; Estados Unidos
Fil: Marcus, Daniel S.. Washington University. School of Medicine; Estados Unidos
Fil: Xiong, Chengjie. Washington University. School of Medicine; Estados Unidos
Fil: Allegri, Ricardo Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Chhatwal, Jasmeer P.. Brigham and Women’s Hospital; Estados Unidos
Fil: Danek, Adrian. Ludwig-Maximilians Universität Munich. Neurologische Klinik; Alemania
Fil: Farlow, Martin R.. Indiana University; Estados Unidos
Fil: Fox, Nick C.. University College London; Estados Unidos
Fil: Ghetti, Bernardino. Indiana University; Estados Unidos
Fil: Graff-Radford, Neill R.. Mayo Clinic; Estados Unidos
Fil: Laske, Christopher. German Center for Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research; Alemania
Fil: Martins, Ralph N.. Edith Cowan University. School of Exercise, Biomedical and Health Sciences. Centre of Excellence for Alzheimer’s Disease Research and Care; Australia
Fil: Masters, Colin L.. University of Melbourne. Mental Health Research Institute; Australia
Fil: Mayeux, Richard P.. Columbia University Medical Center. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain; Estados Unidos
Fil: Ringman, John M.. University of Southern California. Keck School of Medicine; Estados Unidos
Fil: Rossor, Martin N.. University College London; Estados Unidos
Fil: Salloway, Stephen P.. Brown University. Warren Alpert Medical School; Estados Unidos
Fil: Schofield, Peter R.. University of New South Wales; Australia
Fil: Morris, John C.. University of Washington; Estados Unidos
Fil: Bateman, Randall J.. University of Washington; Estados Unidos
Materia
Dominantly Inherited Alzheimer
Neurological
Symptoms
Familial Alzheimer
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/51545

id CONICETDig_578d4b4ba14bd2538ef55f1dbf660149
oai_identifier_str oai:ri.conicet.gov.ar:11336/51545
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)Tang, MengxuanRyman, Davis C.McDade, EricJasielec, Mateusz S.Buckles, Virginia D.Cairns, Nigel J.Fagan, Anne M.Goate, AlisonMarcus, Daniel S.Xiong, ChengjieAllegri, Ricardo FranciscoChhatwal, Jasmeer P.Danek, AdrianFarlow, Martin R.Fox, Nick C.Ghetti, BernardinoGraff-Radford, Neill R.Laske, ChristopherMartins, Ralph N.Masters, Colin L.Mayeux, Richard P.Ringman, John M.Rossor, Martin N.Salloway, Stephen P.Schofield, Peter R.Morris, John C.Bateman, Randall J.Dominantly Inherited AlzheimerNeurologicalSymptomsFamilial Alzheimerhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Background Autosomal dominant familial Alzheimer's disease (ADAD) is a rare disorder with non-amnestic neurological symptoms in some clinical presentations. We aimed to compile and compare data from symptomatic participants in the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) with those reported in the literature to estimate the prevalences of non-amnestic neurological symptoms in participants with ADAD. Methods We prospectively collected data from the DIAN-OBS database, which recruited participants from study centres in the USA, Europe, and Australia, between Feb 29, 2008, and July 1, 2014. We also did a systematic review of publications to extract individual-level clinical data for symptomatic participants with ADAD. We used data for age of onset (from first report of cognitive decline), disease course from onset to death, and the presence of 13 neurological findings that have been reported in association with ADAD. Using multivariable linear regression, we investigated the prevalences of various non-amnestic neurological symptoms and the contributions of age of onset and specific mutation type on symptoms. Findings The DIAN-OBS dataset included 107 individuals with detailed clinical data (forming the DIAN-OBS cohort). Our systematic review yielded 188 publications reporting on 1228 symptomatic individuals, with detailed neurological examination descriptions available for 753 individuals (forming the published data cohort). The most prevalent non-amnestic cognitive manifestations in participants in the DIAN-OBS cohort were those typical of mild to moderate Alzheimer's disease, including visual agnosia (55·1%, 95% CI 45·7–64·6), aphasia (57·9%, 48·6–67·3), and behavioural changes (61·7%, 51·5–70·0). Non-amnestic cognitive manifestations were less prevalent in the published data cohort (eg, visual agnosia [5·6%, 3·9–7·2], aphasia [23·0%, 20·0–26·0], and behavioural changes [31·7%, 28·4–35·1]). Prevalence of non-cognitive neurological manifestations in the DIAN-OBS cohort was low, including myoclonus and spasticity (9·3%, 95% CI 3·8–15·0), and seizures (2·8%, 0·5–5·9) and moderate for parkinsonism (11·2%, 5·3–17·1). By constrast, prevalence was higher in the published data cohort for myoclonus and spasticity (19·4%, 16·6–22·2 and 15·0%, 12·5–17·6, respectively), parkinsonism (12·5%, 10·1–15·0), and seizures (20·3%, 17·4–23·2). In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of onset of symptoms of ADAD (odds ratio 1·09 per 1 year increase in age of onset, 95% CI 1·04–1·14, p=0·0003); and motor symptoms were more common at younger age of onset (myoclonus 0·93, 0·90–0·97, p=0·0007; seizures 0·95, 0·92–0·98, p=0·0018; corticobulbar deficits 0·91, 0·86–0·96, p=0·0012; and cerebellar ataxia 0·82, 0·74–0·91, p=0·0002). In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stages of disease. Interpretation The non-cognitive clinical manifestations of Alzheimer's disease seem to affect a small proportion of participants with mild to moderate ADAD, and are probably influenced by disease severity, environmental, and genetic factors. When evaluating patients with potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disease are the most consistent finding, with some patients manifesting non-cognitive neurological symptoms. Future work is needed to determine the environmental and genetic factors that cause these neurological symptoms. Funding National Institutes of Health and German Center for Neurodegenerative Diseases.Fil: Tang, Mengxuan. Washington University. School of Medicine; Estados UnidosFil: Ryman, Davis C.. Washington University. School of Medicine; Estados UnidosFil: McDade, Eric. Washington University. School of Medicine; Estados UnidosFil: Jasielec, Mateusz S.. Washington University. School of Medicine; Estados UnidosFil: Buckles, Virginia D.. Washington University. School of Medicine; Estados UnidosFil: Cairns, Nigel J.. Washington University. School of Medicine; Estados UnidosFil: Fagan, Anne M.. Washington University. School of Medicine; Estados UnidosFil: Goate, Alison. Washington University. School of Medicine; Estados UnidosFil: Marcus, Daniel S.. Washington University. School of Medicine; Estados UnidosFil: Xiong, Chengjie. Washington University. School of Medicine; Estados UnidosFil: Allegri, Ricardo Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Chhatwal, Jasmeer P.. Brigham and Women’s Hospital; Estados UnidosFil: Danek, Adrian. Ludwig-Maximilians Universität Munich. Neurologische Klinik; AlemaniaFil: Farlow, Martin R.. Indiana University; Estados UnidosFil: Fox, Nick C.. University College London; Estados UnidosFil: Ghetti, Bernardino. Indiana University; Estados UnidosFil: Graff-Radford, Neill R.. Mayo Clinic; Estados UnidosFil: Laske, Christopher. German Center for Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research; AlemaniaFil: Martins, Ralph N.. Edith Cowan University. School of Exercise, Biomedical and Health Sciences. Centre of Excellence for Alzheimer’s Disease Research and Care; AustraliaFil: Masters, Colin L.. University of Melbourne. Mental Health Research Institute; AustraliaFil: Mayeux, Richard P.. Columbia University Medical Center. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain; Estados UnidosFil: Ringman, John M.. University of Southern California. Keck School of Medicine; Estados UnidosFil: Rossor, Martin N.. University College London; Estados UnidosFil: Salloway, Stephen P.. Brown University. Warren Alpert Medical School; Estados UnidosFil: Schofield, Peter R.. University of New South Wales; AustraliaFil: Morris, John C.. University of Washington; Estados UnidosFil: Bateman, Randall J.. University of Washington; Estados UnidosElsevier Science Inc2016-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/51545Tang, Mengxuan; Ryman, Davis C.; McDade, Eric; Jasielec, Mateusz S.; Buckles, Virginia D.; et al.; Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS); Elsevier Science Inc; Lancet Neurology; 15; 13; 12-2016; 1317-13251474-4422CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/S1474-4422(16)30229-0info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:45:03Zoai:ri.conicet.gov.ar:11336/51545instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:45:03.627CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
title Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
spellingShingle Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
Tang, Mengxuan
Dominantly Inherited Alzheimer
Neurological
Symptoms
Familial Alzheimer
title_short Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
title_full Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
title_fullStr Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
title_full_unstemmed Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
title_sort Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)
dc.creator.none.fl_str_mv Tang, Mengxuan
Ryman, Davis C.
McDade, Eric
Jasielec, Mateusz S.
Buckles, Virginia D.
Cairns, Nigel J.
Fagan, Anne M.
Goate, Alison
Marcus, Daniel S.
Xiong, Chengjie
Allegri, Ricardo Francisco
Chhatwal, Jasmeer P.
Danek, Adrian
Farlow, Martin R.
Fox, Nick C.
Ghetti, Bernardino
Graff-Radford, Neill R.
Laske, Christopher
Martins, Ralph N.
Masters, Colin L.
Mayeux, Richard P.
Ringman, John M.
Rossor, Martin N.
Salloway, Stephen P.
Schofield, Peter R.
Morris, John C.
Bateman, Randall J.
author Tang, Mengxuan
author_facet Tang, Mengxuan
Ryman, Davis C.
McDade, Eric
Jasielec, Mateusz S.
Buckles, Virginia D.
Cairns, Nigel J.
Fagan, Anne M.
Goate, Alison
Marcus, Daniel S.
Xiong, Chengjie
Allegri, Ricardo Francisco
Chhatwal, Jasmeer P.
Danek, Adrian
Farlow, Martin R.
Fox, Nick C.
Ghetti, Bernardino
Graff-Radford, Neill R.
Laske, Christopher
Martins, Ralph N.
Masters, Colin L.
Mayeux, Richard P.
Ringman, John M.
Rossor, Martin N.
Salloway, Stephen P.
Schofield, Peter R.
Morris, John C.
Bateman, Randall J.
author_role author
author2 Ryman, Davis C.
McDade, Eric
Jasielec, Mateusz S.
Buckles, Virginia D.
Cairns, Nigel J.
Fagan, Anne M.
Goate, Alison
Marcus, Daniel S.
Xiong, Chengjie
Allegri, Ricardo Francisco
Chhatwal, Jasmeer P.
Danek, Adrian
Farlow, Martin R.
Fox, Nick C.
Ghetti, Bernardino
Graff-Radford, Neill R.
Laske, Christopher
Martins, Ralph N.
Masters, Colin L.
Mayeux, Richard P.
Ringman, John M.
Rossor, Martin N.
Salloway, Stephen P.
Schofield, Peter R.
Morris, John C.
Bateman, Randall J.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Dominantly Inherited Alzheimer
Neurological
Symptoms
Familial Alzheimer
topic Dominantly Inherited Alzheimer
Neurological
Symptoms
Familial Alzheimer
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background Autosomal dominant familial Alzheimer's disease (ADAD) is a rare disorder with non-amnestic neurological symptoms in some clinical presentations. We aimed to compile and compare data from symptomatic participants in the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) with those reported in the literature to estimate the prevalences of non-amnestic neurological symptoms in participants with ADAD. Methods We prospectively collected data from the DIAN-OBS database, which recruited participants from study centres in the USA, Europe, and Australia, between Feb 29, 2008, and July 1, 2014. We also did a systematic review of publications to extract individual-level clinical data for symptomatic participants with ADAD. We used data for age of onset (from first report of cognitive decline), disease course from onset to death, and the presence of 13 neurological findings that have been reported in association with ADAD. Using multivariable linear regression, we investigated the prevalences of various non-amnestic neurological symptoms and the contributions of age of onset and specific mutation type on symptoms. Findings The DIAN-OBS dataset included 107 individuals with detailed clinical data (forming the DIAN-OBS cohort). Our systematic review yielded 188 publications reporting on 1228 symptomatic individuals, with detailed neurological examination descriptions available for 753 individuals (forming the published data cohort). The most prevalent non-amnestic cognitive manifestations in participants in the DIAN-OBS cohort were those typical of mild to moderate Alzheimer's disease, including visual agnosia (55·1%, 95% CI 45·7–64·6), aphasia (57·9%, 48·6–67·3), and behavioural changes (61·7%, 51·5–70·0). Non-amnestic cognitive manifestations were less prevalent in the published data cohort (eg, visual agnosia [5·6%, 3·9–7·2], aphasia [23·0%, 20·0–26·0], and behavioural changes [31·7%, 28·4–35·1]). Prevalence of non-cognitive neurological manifestations in the DIAN-OBS cohort was low, including myoclonus and spasticity (9·3%, 95% CI 3·8–15·0), and seizures (2·8%, 0·5–5·9) and moderate for parkinsonism (11·2%, 5·3–17·1). By constrast, prevalence was higher in the published data cohort for myoclonus and spasticity (19·4%, 16·6–22·2 and 15·0%, 12·5–17·6, respectively), parkinsonism (12·5%, 10·1–15·0), and seizures (20·3%, 17·4–23·2). In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of onset of symptoms of ADAD (odds ratio 1·09 per 1 year increase in age of onset, 95% CI 1·04–1·14, p=0·0003); and motor symptoms were more common at younger age of onset (myoclonus 0·93, 0·90–0·97, p=0·0007; seizures 0·95, 0·92–0·98, p=0·0018; corticobulbar deficits 0·91, 0·86–0·96, p=0·0012; and cerebellar ataxia 0·82, 0·74–0·91, p=0·0002). In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stages of disease. Interpretation The non-cognitive clinical manifestations of Alzheimer's disease seem to affect a small proportion of participants with mild to moderate ADAD, and are probably influenced by disease severity, environmental, and genetic factors. When evaluating patients with potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disease are the most consistent finding, with some patients manifesting non-cognitive neurological symptoms. Future work is needed to determine the environmental and genetic factors that cause these neurological symptoms. Funding National Institutes of Health and German Center for Neurodegenerative Diseases.
Fil: Tang, Mengxuan. Washington University. School of Medicine; Estados Unidos
Fil: Ryman, Davis C.. Washington University. School of Medicine; Estados Unidos
Fil: McDade, Eric. Washington University. School of Medicine; Estados Unidos
Fil: Jasielec, Mateusz S.. Washington University. School of Medicine; Estados Unidos
Fil: Buckles, Virginia D.. Washington University. School of Medicine; Estados Unidos
Fil: Cairns, Nigel J.. Washington University. School of Medicine; Estados Unidos
Fil: Fagan, Anne M.. Washington University. School of Medicine; Estados Unidos
Fil: Goate, Alison. Washington University. School of Medicine; Estados Unidos
Fil: Marcus, Daniel S.. Washington University. School of Medicine; Estados Unidos
Fil: Xiong, Chengjie. Washington University. School of Medicine; Estados Unidos
Fil: Allegri, Ricardo Francisco. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Chhatwal, Jasmeer P.. Brigham and Women’s Hospital; Estados Unidos
Fil: Danek, Adrian. Ludwig-Maximilians Universität Munich. Neurologische Klinik; Alemania
Fil: Farlow, Martin R.. Indiana University; Estados Unidos
Fil: Fox, Nick C.. University College London; Estados Unidos
Fil: Ghetti, Bernardino. Indiana University; Estados Unidos
Fil: Graff-Radford, Neill R.. Mayo Clinic; Estados Unidos
Fil: Laske, Christopher. German Center for Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research; Alemania
Fil: Martins, Ralph N.. Edith Cowan University. School of Exercise, Biomedical and Health Sciences. Centre of Excellence for Alzheimer’s Disease Research and Care; Australia
Fil: Masters, Colin L.. University of Melbourne. Mental Health Research Institute; Australia
Fil: Mayeux, Richard P.. Columbia University Medical Center. Taub Institute for Research on Alzheimer’s Disease and the Aging Brain; Estados Unidos
Fil: Ringman, John M.. University of Southern California. Keck School of Medicine; Estados Unidos
Fil: Rossor, Martin N.. University College London; Estados Unidos
Fil: Salloway, Stephen P.. Brown University. Warren Alpert Medical School; Estados Unidos
Fil: Schofield, Peter R.. University of New South Wales; Australia
Fil: Morris, John C.. University of Washington; Estados Unidos
Fil: Bateman, Randall J.. University of Washington; Estados Unidos
description Background Autosomal dominant familial Alzheimer's disease (ADAD) is a rare disorder with non-amnestic neurological symptoms in some clinical presentations. We aimed to compile and compare data from symptomatic participants in the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) with those reported in the literature to estimate the prevalences of non-amnestic neurological symptoms in participants with ADAD. Methods We prospectively collected data from the DIAN-OBS database, which recruited participants from study centres in the USA, Europe, and Australia, between Feb 29, 2008, and July 1, 2014. We also did a systematic review of publications to extract individual-level clinical data for symptomatic participants with ADAD. We used data for age of onset (from first report of cognitive decline), disease course from onset to death, and the presence of 13 neurological findings that have been reported in association with ADAD. Using multivariable linear regression, we investigated the prevalences of various non-amnestic neurological symptoms and the contributions of age of onset and specific mutation type on symptoms. Findings The DIAN-OBS dataset included 107 individuals with detailed clinical data (forming the DIAN-OBS cohort). Our systematic review yielded 188 publications reporting on 1228 symptomatic individuals, with detailed neurological examination descriptions available for 753 individuals (forming the published data cohort). The most prevalent non-amnestic cognitive manifestations in participants in the DIAN-OBS cohort were those typical of mild to moderate Alzheimer's disease, including visual agnosia (55·1%, 95% CI 45·7–64·6), aphasia (57·9%, 48·6–67·3), and behavioural changes (61·7%, 51·5–70·0). Non-amnestic cognitive manifestations were less prevalent in the published data cohort (eg, visual agnosia [5·6%, 3·9–7·2], aphasia [23·0%, 20·0–26·0], and behavioural changes [31·7%, 28·4–35·1]). Prevalence of non-cognitive neurological manifestations in the DIAN-OBS cohort was low, including myoclonus and spasticity (9·3%, 95% CI 3·8–15·0), and seizures (2·8%, 0·5–5·9) and moderate for parkinsonism (11·2%, 5·3–17·1). By constrast, prevalence was higher in the published data cohort for myoclonus and spasticity (19·4%, 16·6–22·2 and 15·0%, 12·5–17·6, respectively), parkinsonism (12·5%, 10·1–15·0), and seizures (20·3%, 17·4–23·2). In an analysis of the published data cohort, ischaemic stroke was more prevalent at older ages of onset of symptoms of ADAD (odds ratio 1·09 per 1 year increase in age of onset, 95% CI 1·04–1·14, p=0·0003); and motor symptoms were more common at younger age of onset (myoclonus 0·93, 0·90–0·97, p=0·0007; seizures 0·95, 0·92–0·98, p=0·0018; corticobulbar deficits 0·91, 0·86–0·96, p=0·0012; and cerebellar ataxia 0·82, 0·74–0·91, p=0·0002). In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stages of disease. Interpretation The non-cognitive clinical manifestations of Alzheimer's disease seem to affect a small proportion of participants with mild to moderate ADAD, and are probably influenced by disease severity, environmental, and genetic factors. When evaluating patients with potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disease are the most consistent finding, with some patients manifesting non-cognitive neurological symptoms. Future work is needed to determine the environmental and genetic factors that cause these neurological symptoms. Funding National Institutes of Health and German Center for Neurodegenerative Diseases.
publishDate 2016
dc.date.none.fl_str_mv 2016-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/51545
Tang, Mengxuan; Ryman, Davis C.; McDade, Eric; Jasielec, Mateusz S.; Buckles, Virginia D.; et al.; Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS); Elsevier Science Inc; Lancet Neurology; 15; 13; 12-2016; 1317-1325
1474-4422
CONICET Digital
CONICET
url http://hdl.handle.net/11336/51545
identifier_str_mv Tang, Mengxuan; Ryman, Davis C.; McDade, Eric; Jasielec, Mateusz S.; Buckles, Virginia D.; et al.; Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS); Elsevier Science Inc; Lancet Neurology; 15; 13; 12-2016; 1317-1325
1474-4422
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1016/S1474-4422(16)30229-0
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier Science Inc
publisher.none.fl_str_mv Elsevier Science Inc
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842268706267201536
score 13.13397